Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline;Derrame pleural e hipertensión pulmonar en un paciente con enfermedad de Parkinson en tratamiento con cabergolina

Archivos de Bronconeumologia

Volumn 45, Issue 2, 2009, Pages 100-102

  Haro Estarriol, Manuel ^a   Sabater Talaverano, Gladis ^a   Rodríguez Jerez, Francisco ^a   Obrador Lagares, Anton ^a   Genís Batlle, David ^b   Sendra Salillas, Salvi ^a  

^a Servicio de Neumología   (Spain)

^b Servicio de Neurología   (Spain)

Author keywords

Cabergoline; Parkinson disease; Pleural effusion; Pulmonary hypertension

Indexed keywords

CABERGOLINE; LEVODOPA; METHYLPHENIDATE; RASAGILINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; MALE; PARKINSON DISEASE; PLEURA EFFUSION; PULMONARY HYPERTENSION; SYMPTOM;

EID: 59849098601     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(09)70782-7     Document Type: Article

References (17)

1. Nutt J.G., and Wooten G.F. Diagnosis and initial management of Parkinson's disease. N Engl J Med 353 (2005) 1021-1027
2. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med 339 (1998) 1130-1143
3. Korczyn A.D., and Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 62 (2002) 775-786
4. Villavicencio C., Ramírez A., Gayete A., Grau S., and Orozco M. Toxicidad pleuropulmonar precoz asociada al tratamiento con cabergolina, un fármaco antiparkinsoniano. Arch Bronconeumol 43 (2007) 519-522
5. Cooper J.A., White D.A., and Matthay R.A. Drug-induced pulmonary disease (part 2). Noncytotoxic drugs. Am Rev Respir Dis 133 (1986) 488-505
6. Haro M., Rubio M., and Puig J. Enfermedad pulmonar asociada a la administración de fluoxetina. Arch Bronconeumol 38 (2002) 153
7. Pfitzenmeyer P., Foucher P., Dennewald G., Chevalon B., Debieuvre D., Bensa P., et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 9 (1996) 1013-1019
8. Curran M.P., and Perry C.M. Cabergoline. A review of its use in the treatment of Parkinson's disease. Drugs. 64 (2004) 2125-2141
9. Frans E., Dom R., and Demedts M. Pulmonary changes during treatment of Parkinson's disease with long-acting ergot derivative, cabergoline. Eur Respir J 5 (1992) 263-265
10. Frank W., Moritz R., Becke B., and Pauli R. Low dose cabergoline induced interstitial pneumonitis. Eur Respir J 14 (1999) 968-970
11. Townsend M., and Maclver D.H. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment in Parkinson's disease. Heart 90 (2004) 47-48
12. Morelock S.Y., and Sahn S.A. Drugs and the pleura. Chest 116 (1999) 212-221
13. Villena V., Ferrer J., Hernández L., De Pablo A., Pérez E., Rodríguez F., et al. Normativa SEPAR: diagnóstico y tratamiento del derrame pleural. Arch Bronconeumol 42 (2006) 349-372
14. Newman-Tancredi A., Cussac D., Quentric Y., Touzard M., Verrièle L., Carpentier N., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303 (2002) 815-822
15. Schade R., Andersohn F., Suissa S., Haverkamp W., and Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 (2007) 29-38
16. Higenbottam T., Laude L., Emery C., and Essener M. Pulmonary hypertension as a result of drug therapy. Clin Chest Med 25 (2004) 123-131
17. Villena V. ¿De qué nos informa el líquido pleural?. Arch Bronconeumol 39 (2003) 193-194